October 14, 2024 – Goldea Capital

CTS Corporation Announces Date for Third Quarter 2024 Earnings Release and Conference Call

Written by Customer Service on October 14, 2024. Posted in Public Companies.

LISLE, Ill., Oct. 14, 2024 (GLOBE NEWSWIRE) — CTS Corporation (NYSE: CTS) will release its earnings for the third quarter 2024 at approximately 8:00 a.m. (ET) on Tuesday, October 29, 2024. A conference call to discuss third quarter 2024 results with management is scheduled for Tuesday, October 29, 2024 at 10:00 a.m. (ET). The dial-in numbers for access from the U.S. are: +1-833-470-1428 (Toll-Free) and +1-404-975-4839 (Local), if calling from outside the U.S., please refer to Global Dial In Numbers to identify the applicable dial-in number for your location. The passcode is 230766. A live audio webcast of the conference call will be available and can be accessed directly from the Investors section of the website of CTS Corporation at https://investors.ctscorp.com/news-events/events-and-presentations/ where it will be archived for...

Tevogen CEO Reaffirms the Company’s Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue Projections

Written by Customer Service on October 14, 2024. Posted in Public Companies.

WARREN, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) — Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, plans to update shareholders on multi-billion dollar asset valuation following this week’s $1b+ revenue potential announcement. “Our shareholders have placed their trust in us, and that is a privilege we take with the utmost seriousness. We are committed to closing the information gap to safeguard their interests and ensure they have full visibility into Tevogen Bio’s progress. This week, we will report on the substantial revenue potential of our pipeline, and in the near future, we will provide a comprehensive update on our asset valuation,” remarked Ryan...

ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of September 2024

Written by Customer Service on October 14, 2024. Posted in Public Companies.

DENVER, Oct. 14, 2024 (GLOBE NEWSWIRE) — ArrowMark Financial Corp., (NASDAQ: BANX) (“ArrowMark Financial”), today announced that BANX’s estimated and unaudited Net Asset Value (“NAV”) as of September 30, 2024, was $21.73. This estimated NAV is not a comprehensive statement of our financial condition or results for the month ended September 30, 2024. About ArrowMark Financial Corp. ArrowMark Financial Corp. is an SEC registered non-diversified, closed-end fund listed on the NASDAQ Global Select Market under the symbol “BANX.” Its investment objective is to provide shareholders with current income. BANX pursues its objective by investing primarily in regulatory capital securities of financial institutions. BANX is managed by ArrowMark Asset Management, LLC. To learn more, visit ir.arrowmarkfinancialcorp.com, or contact...

Atossa Therapeutics to Present at the 2024 Maxim Healthcare Virtual Summit

Written by Customer Service on October 14, 2024. Posted in Public Companies.

SEATTLE, Oct. 14, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), today announced that Michael Parks, Vice President, Investor and Public Relations, will participate in a virtual fireside chat on Wednesday, October 16, 2024 at 12:00 p.m. EDT at the 2024 Maxim Healthcare Virtual Summit. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer. Interested parties can register and access the live webcast for the conference here. About Atossa Therapeutics Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast...

Winnebago Industries Expands Responsibilities of Don Clark to Lead Winnebago Brand’s Towable RV Division

Written by Customer Service on October 14, 2024. Posted in Public Companies.

EDEN PRAIRIE, Minn., Oct. 14, 2024 (GLOBE NEWSWIRE) — Winnebago Industries, Inc. (NYSE: WGO) today announced that Don Clark, president of Grand Design RV, has been promoted to Group President, Towable RVs, and will now lead the Winnebago brand’s towable RV division in addition to the Grand Design RV brand, leveraging the company’s significant overall towables expertise and skills in Northern Indiana, effective November 1. “Don is a hall-of-famer with an unmatched track record of success and understanding of the RV industry, especially the towable RV market,” said Winnebago Industries President and CEO, Michael Happe. “Don’s insights, operational acumen, and extensive knowledge of what it takes to win in this space make him the ideal and logical choice to lead the team during their next evolution. With the recent appointment of...

Shoals Technologies Group, Inc. Announces Third Quarter 2024 Earnings Release Date and Conference Call

Written by Customer Service on October 14, 2024. Posted in Public Companies.

PORTLAND, Tenn., Oct. 14, 2024 (GLOBE NEWSWIRE) — Shoals Technologies Group, Inc. (the “Company”) (Nasdaq: SHLS) today announced that the Company will release its third quarter 2024 results before market open on Tuesday, November 12, 2024, to be followed by a conference call at 8:00 a.m. (Eastern Time) on the same day. Interested investors and other parties can access the live webcast through the Investor Relations section of the Company’s website at https://investors.shoals.com. An archived replay of the webcast will be available shortly after the event concludes. About Shoals Technologies Group, Inc.Shoals Technologies Group is a leading provider of electrical balance of systems (“EBOS”) solutions for the energy transition market. Since its founding in 1996, the Company has introduced innovative technologies and systems...

Legacy Housing Corporation Announces Timing of Third Quarter 2024 Earnings Release and Conference Call

Written by Customer Service on October 14, 2024. Posted in Public Companies.

BEDFORD, Texas, Oct. 14, 2024 (GLOBE NEWSWIRE) — Legacy Housing Corporation (“Legacy” or the “Company”, NASDAQ: LEGH) will release its financial results for the third quarter ended September 30, 2024, after markets close on Tuesday, November 12, 2024. The Company will then host a conference call at 10:00 a.m. Central Time on Wednesday, November 13, 2024. To access the conference call, please pre-register using this link. Registrants will receive confirmation with dial-in details. A replay of the webcast will be available on https://investors.legacyhousingcorp.com/ starting approximately two hours after the call and will be archived on the site for one year. About Legacy Housing Corporation Legacy builds, sells, and finances manufactured homes and “tiny houses” that are distributed through a network of independent retailers...

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

Written by Customer Service on October 14, 2024. Posted in Public Companies.

Data presentations highlight the results for FILSPARI® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan’s effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27, 2024. Presentations will include new data from the SPARTAN Study highlighting efficacy and safety results of FILSPARI (sparsentan) in IgA nephropathy (IgAN) when used as a first-line treatment...

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024

Written by Customer Service on October 14, 2024. Posted in Public Companies.

Information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 09/30/2024 96,501,526 Total gross of voting rights: 96,501,526 Total net* of voting rights: 96,199,467 * Net total = total number of voting rights attached to shares – shares without voting rights Attachment PDF Version

Bel Announces Appointment of Umasankar (‘Uma”) Pingali as Global Head of Sales and Marketing

Written by Customer Service on October 14, 2024. Posted in Public Companies.

WEST ORANGE, N.J., Oct. 14, 2024 (GLOBE NEWSWIRE) — Bel Fuse Inc. (“Bel,” or, “the Company”) (Nasdaq:BELFA and Nasdaq:BELFB), today announced its appointment of Uma Pingali as Global Head of Sales and Marketing, a newly created role. With over 30 years of management experience in global sales, marketing, business development within the electronic industry, Uma is uniquely positioned to lead and accelerate Bel’s sales and marketing organizations. His experience with integrating various sales teams that have joined via acquisitions will be very helpful for Bel with our history of acquisitions. Uma started his career in India and has lived and led sales organizations there and in Singapore, China, Hong Kong and the U.S. In his most recent role as President of Global Sales at Farnell, based in Chicago, Uma managed a team of 600+ people...

Day: October 14, 2024

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice